RMD: ResMed — Sleep Tech Growth Meets Attractive Valuation
ResMed ($RMD) shows durable fundamentals, double-digit top-line growth and a robust balance sheet while trading ~25% below its 52-week high. Analysts are broadly bullish, citing large sleep-tech market expansion and recurring revenue streams.
Executive Summary
Investment Thesis: ResMed ($RMD) is positioned as a leading player in sleep-disordered breathing devices and patient monitoring with recurring device and software revenue. Recent quarterly results showed mid-to-high single-digit to low double-digit revenue growth and solid EPS, and management keeps a conservative yet stable outlook. The company benefits from a large and fast-growing sleep tech market, strong margins and a healthy balance sheet, while valuation sits below many analyst targets which implies material upside. Near-term risk includes competitive pressure and sensitivity to device replacement cycles and macro demand.
Current Price: $220.58 | Key Metric: P/E 21.62 | Stance: BULLISH
Company Overview
ResMed Inc designs, manufactures and sells cloud-connected medical devices and software for treating sleep-disordered breathing and other chronic respiratory conditions. The company supplies CPAP devices, masks, ventilators and remote patient monitoring software to health care providers, sleep clinics and consumers globally.
Key Products & Competitive Position
- Core Business: Sleep apnea treatment devices, masks and associated subscription and software services for adherence and remote patient monitoring.
- Key Products: AirSense and AirCurve device families, reusable and disposable masks, myAir and cloud-based patient management platforms plus expanding ventilator and monitoring offerings.
- Competitive Moat: Strong brand recognition, integrated hardware plus cloud software ecosystem, extensive clinical relationships and a large installed device base that feeds recurring software and consumable revenue.
Recent Developments
ResMed reported strong Q4 revenue momentum with quarterly revenue of roughly $1.42 billion, about 11% year-over-year growth. Analysts and investors have focused on the company’s move toward expanded patient monitoring and software monetization. Industry reports also highlight a rapidly expanding sleep tech market with projected double-digit CAGRs, which supports structural demand for ResMed’s offerings.
Financial Snapshot
Revenue & Earnings Trends
Revenue growth has been positive and consistent, with the company reporting quarterly revenue of approximately $1.42 billion for the referenced quarter, representing around 11% year-over-year growth. EPS (TTM) stands at $10.12 and the trailing P/E is about 21.6. Profitability remains healthy, supported by high gross margins typical of a hardware-plus-software model and operating leverage as software subscription adoption grows.
Balance Sheet Highlights
ResMed carries a conservative liquidity profile. The current ratio is about 3.06, indicating strong short-term liquidity, and the firm has manageable leverage relative to peers. Free cash flow has historically been solid, which supports dividends, buybacks and continued R&D investment into monitoring and software capabilities.
Valuation Analysis
Current Valuation Metrics
Historical Comparison
On a trailing basis the P/E sits in the low- to mid-20s. This is modestly below some periods in ResMed’s recent five-year history when multiples expanded into the mid-to-high 20s. That compresses partly because the stock is trading about 25% below its 52-week high, creating a valuation gap versus analyst price targets and historical peaks.
Fair Value Estimate
Combining a forward P/E near 19, a PEG near 1.6 and steady free cash flow generation suggests a fair value range roughly in the $270 to $320 band under reasonable growth scenarios. Analysts’ mean target of $296.87 aligns with the midpoint of this range, implying material upside from the current price while leaving room for downside if growth slows or competitive headwinds intensify.
Competitive Landscape
Market Position
Market Share: Leading share in CPAP devices and a top position in sleep therapy hardware globally | Ranking: #1-2 in the sleep-disordered breathing device market
Key Competitors
Competitive Advantages
- Moat 1: Integrated device and cloud software ecosystem that locks in clinicians and patients through recurring data and services.
- Moat 2: Strong brand and scale in manufacturing and clinical support which lowers unit costs and improves adoption.
- Moat 3: Large installed base that generates recurring consumable sales and subscription revenue, smoothing revenue cyclicality.
Earnings Track Record
Last 4 Quarters: 3 beats / 1 misses
Recent Earnings History
Guidance Trend
Management’s guidance has been relatively cautious and focused on margin expansion through higher software penetration and cost discipline. Analysts have noted that guidance has been modestly conservative recently, which can leave upside if demand normalizes or adoption accelerates.
Analyst Sentiment
Consensus Rating:
Price Targets
- Low: $230
- Mean: $296.87 (+34.6% upside)
- High: $345
Recent Analyst Actions
Citigroup maintained a Buy and raised its price target to $345 on 2/2/2026, highlighting recurring revenue and software monetization upside. The analyst community has generally raised targets during the past 6-9 months as the market framed ResMed more as a software-enabled medical device leader rather than a pure hardware cycle play.
Recent News & Catalysts
Key Developments
- Unpacking Q4 Earnings (3/26/2026): Commentary and comparisons across patient monitoring stocks highlighted ResMed’s performance in the context of its peers, with analysts noting solid revenue but mixed sentiment after the print.
- Market Report (3/25/2026): A Healthcare Foresights market study projects the global sleep tech devices market reaching roughly $134.6 billion by 2035 at an 18.46% CAGR, which supports long-term structural tailwinds for RMD.
- Analyst Target Changes: Notable upgrades and target raises, including Citigroup’s increase to $345, have influenced the consensus mean and investor expectations.
Upcoming Catalysts
Next Earnings: 2026-04-23 After Market | Key Events: Management commentary on guidance, software ARR growth, device shipment cadence and margin outlook
Technical Outlook
Current Price: $220.58 vs 52-Week High: $293.81 (-24.9% from high)
Trend Analysis
The stock has pulled back from last summer’s peak and is trading nearer the lower half of its 52-week range. Momentum indicators point to a neutral-to-slightly-bullish posture as the pullback has held above the important $200 area. Volume has contracted relative to the 12-month average which suggests the current consolidation may be digestion rather than a new downtrend.
Key Levels
- Resistance: $235, $260
- Support: $200, $210
Bull vs Bear Case
Bull Case
- Catalyst 1: Faster than expected software and monitoring adoption boosts recurring revenue, improving margins and FCF conversion.
- Catalyst 2: Large addressable market expansion in sleep tech and remote patient monitoring that drives prolonged device replacement cycles and consumable sales.
- Catalyst 3: Recent analyst target upgrades and conservative guidance leave room for upside surprises on revenue and margin beats.
Bull Target: $345 (+56.4%)
Bear Case
- Risk 1: Intensifying competition and pricing pressure in devices, or faster commoditization of masks and lower-margin accessories.
- Risk 2: Macro weakness that delays elective purchases and replacement cycles, compressing near-term revenue growth.
- Risk 3: Execution risk around scaling software monetization and integrating patient monitoring solutions, which could cap margins if adoption lags.
Bear Target: $180 (-18.4%)
Risks to Consider
- Valuation Risk: Despite a compelling analyst mean target, multiples already price in continued software growth. A sustained slowdown would pressure the P/E multiple.
- Competitive Risk: New entrants and lower-cost alternatives could erode pricing power for devices and masks.
- Macro Risk: Device replacement cycles and elective upgrades are sensitive to consumer and healthcare spending trends.
- Execution Risk: Software monetization and push into broader patient monitoring require execution across sales, clinical adoption and regulatory pathways.
Bottom Line
Investment Verdict: BULLISH
ResMed presents a balanced growth story with durable demand for sleep therapy and expanding software revenues that improve margin visibility. The consensus analyst targets and current valuation suggest meaningful upside, but near-term performance will hinge on upcoming earnings and clarity on software subscription traction. Are the longer-term secular drivers priced in, or does the current pullback create an asymmetric risk/reward for anyone watching this space?
Action Items for Investors
- Long-term investors: Track software ARR growth, installed-base monetization and free cash flow trends to assess whether long-term targets remain achievable.
- Short-term traders: Monitor the Apr 23 earnings print, guidance tone, and price reaction around the $210 to $235 band for tactical setups and risk-defined entries.
- Risk management: Keep position sizes aligned with your risk tolerance, watch key support levels near $200, and pay attention to guidance revisions that could trigger volatility.
What to Watch This Week
- Management commentary and guidance at the next earnings release on 2026-04-23.
- Analyst note flow and any additional target changes, following Citigroup’s raise to $345 earlier this year.
- Industry data on sleep tech market growth and any competitive product launches or regulatory updates.
Sources
Share this report
Share this article
Spread the word on social media
Think RMD will outperform? Prove it.
Free practice contests — earn Alpha CoinsExplore More Content
Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.